Compare McDonald's Corp (MCD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs State Street SPDR S&P Biotech ETF — how do they compare? McDonald's Corp trades at $267.25 (market cap $190.16B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: McDonald's Corp pays a 2.78% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McDonald's Corp nearer its low. Which is the better fit depends on your goals.
| MCD | XBI | |
|---|---|---|
Market Cap | $190.16B | — |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $341.06 | $164.28 |
52-Week Low | $264.54 | $85.16 |
Enterprise Value | $243.87B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's stock trades at $267.64, down slightly by 0.03% on the day, and is currently in a bearish technical trend according to moving averages. The company reported Q1 2026 earnings that beat expectations with EPS of $2.83 versus $2.74 expected, and revenue growth remains steady, reaching $26.89 billion in 2025. Recent news highlights the launch of the 'McDonald's NEXT' growth strategy focusing on automation and improved customer experience to counter competitive pressures.
The outlook for McDonald's is supported by strong fundamentals including a high net income margin of 31.62% and a consensus analyst price target of $329, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Investor sentiment is mixed with a bearish technical signal but optimistic analyst ratings, with 58% recommending buy.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
